Moderate and Severe Chronic Kidney Disease - Pipeline Insight, 2021
This report can be delivered to the clients within 48-72 Hours
DelveInsight’s, “Moderate and Severe Chronic Kidney Disease - Pipeline Insight, 2021,” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Moderate and Severe Chronic Kidney Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Moderate and Severe Chronic Kidney Disease: Overview
Chronic kidney disease, also called chronic kidney failure, describes the gradual loss of kidney function. Kidney function is measured by how well the kidneys clean the blood. The glomerular filtration rate (GFR) is a good way to find out the patient's stage of kidney disease. The stages range from very mild (stage 1) to kidney failure (stage 5). Stage 3A Moderate CKD (GFR = 45-59 mL/min), Stage 3B Moderate CKD (GFR = 30-44 mL/min), and Stage 4 Severe CKD (GFR = 15-29 mL/min). Determining the cause of CKD distinguishes whether the patient has a systemic condition or a localized condition in the kidney such as glomerular disease because this functionality affects management.
“Moderate and Severe Chronic Kidney Disease - Pipeline Insight, 2021” report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Moderate and Severe Chronic Kidney Disease pipeline landscape is provided which includes the disease overview and Moderate and Severe Chronic Kidney Disease treatment guidelines. The assessment part of the report embraces, in depth Moderate and Severe Chronic Kidney Disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Moderate and Severe Chronic Kidney Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Moderate and Severe Chronic Kidney Disease R&D. The therapies under development are focused on novel approaches to treat/improve Moderate and Severe Chronic Kidney Disease.
Moderate and Severe Chronic Kidney Disease Emerging Drugs Chapters
This segment of the Moderate and Severe Chronic Kidney Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Moderate and Severe Chronic Kidney Disease Emerging Drugs
KBP-5074: KBP Biosciences
KBP-5074 is a third-generation non-steroidal mineralocorticoid receptor antagonist (MRA) with a unique pharmacokinetic (PK) profile characterized by a longer half-life and increased mineralocorticoid receptor (MR) affinity than current MRAs. KBP-5074 is currently evaluating patients in a global Phase 2b study evaluating its ability to treat uncontrolled hypertension and cardiorenal disease in stage 3b/4 Chronic Kidney Disease (CKD) patients who are at high risk of hyperkalemia and for whom existing MRAs are contraindicated.
ELIXCYTE: UnicoCell Biomed
ELIXCYTE is an allogeneic adipose stem cell product and is currently undergoing two human clinical trials. For chronic kidney disease (CKD) treatment (NCT02933827), the phase-II clinical trial is ongoing.
Further product details are provided in the report……..
Moderate and Severe Chronic Kidney Disease: Therapeutic Assessment
This segment of the report provides insights about the different Moderate and Severe Chronic Kidney Disease drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Moderate and Severe Chronic Kidney Disease
There are approx. 4+ key companies which are developing the therapies for Moderate and Severe Chronic Kidney Disease. The companies which have their Moderate and Severe Chronic Kidney Disease drug candidates in the most advanced stage, i.e. phase II include, KBP Bioscience.
Phases
DelveInsight’s report covers around 4+ products under different phases of clinical development like
Moderate and Severe Chronic Kidney Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Moderate and Severe Chronic Kidney Disease: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Moderate and Severe Chronic Kidney Disease therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Moderate and Severe Chronic Kidney Disease drugs.
Moderate and Severe Chronic Kidney Disease Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Moderate and Severe Chronic Kidney Disease - Pipeline Insight, 2021,” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Moderate and Severe Chronic Kidney Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Moderate and Severe Chronic Kidney Disease: Overview
Chronic kidney disease, also called chronic kidney failure, describes the gradual loss of kidney function. Kidney function is measured by how well the kidneys clean the blood. The glomerular filtration rate (GFR) is a good way to find out the patient's stage of kidney disease. The stages range from very mild (stage 1) to kidney failure (stage 5). Stage 3A Moderate CKD (GFR = 45-59 mL/min), Stage 3B Moderate CKD (GFR = 30-44 mL/min), and Stage 4 Severe CKD (GFR = 15-29 mL/min). Determining the cause of CKD distinguishes whether the patient has a systemic condition or a localized condition in the kidney such as glomerular disease because this functionality affects management.
“Moderate and Severe Chronic Kidney Disease - Pipeline Insight, 2021” report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Moderate and Severe Chronic Kidney Disease pipeline landscape is provided which includes the disease overview and Moderate and Severe Chronic Kidney Disease treatment guidelines. The assessment part of the report embraces, in depth Moderate and Severe Chronic Kidney Disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Moderate and Severe Chronic Kidney Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Moderate and Severe Chronic Kidney Disease R&D. The therapies under development are focused on novel approaches to treat/improve Moderate and Severe Chronic Kidney Disease.
Moderate and Severe Chronic Kidney Disease Emerging Drugs Chapters
This segment of the Moderate and Severe Chronic Kidney Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Moderate and Severe Chronic Kidney Disease Emerging Drugs
KBP-5074: KBP Biosciences
KBP-5074 is a third-generation non-steroidal mineralocorticoid receptor antagonist (MRA) with a unique pharmacokinetic (PK) profile characterized by a longer half-life and increased mineralocorticoid receptor (MR) affinity than current MRAs. KBP-5074 is currently evaluating patients in a global Phase 2b study evaluating its ability to treat uncontrolled hypertension and cardiorenal disease in stage 3b/4 Chronic Kidney Disease (CKD) patients who are at high risk of hyperkalemia and for whom existing MRAs are contraindicated.
ELIXCYTE: UnicoCell Biomed
ELIXCYTE is an allogeneic adipose stem cell product and is currently undergoing two human clinical trials. For chronic kidney disease (CKD) treatment (NCT02933827), the phase-II clinical trial is ongoing.
Further product details are provided in the report……..
Moderate and Severe Chronic Kidney Disease: Therapeutic Assessment
This segment of the report provides insights about the different Moderate and Severe Chronic Kidney Disease drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Moderate and Severe Chronic Kidney Disease
There are approx. 4+ key companies which are developing the therapies for Moderate and Severe Chronic Kidney Disease. The companies which have their Moderate and Severe Chronic Kidney Disease drug candidates in the most advanced stage, i.e. phase II include, KBP Bioscience.
Phases
DelveInsight’s report covers around 4+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Moderate and Severe Chronic Kidney Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Parenteral
- intravitreal
- Subretinal
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Moderate and Severe Chronic Kidney Disease: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Moderate and Severe Chronic Kidney Disease therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Moderate and Severe Chronic Kidney Disease drugs.
Moderate and Severe Chronic Kidney Disease Report Insights
- Moderate and Severe Chronic Kidney Disease Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Moderate and Severe Chronic Kidney Disease drugs?
- How many Moderate and Severe Chronic Kidney Disease drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Moderate and Severe Chronic Kidney Disease?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Moderate and Severe Chronic Kidney Disease therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Moderate and Severe Chronic Kidney Disease and their status?
- What are the key designations that have been granted to the emerging drugs?
- KBP Bioscience
- UnicoCell Biomed
- KBP-5074
- ELIXCYTE
Introduction
Executive Summary
Moderate and Severe Chronic Kidney Disease: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Moderate and Severe Chronic Kidney Disease – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Moderate and Severe Chronic Kidney Disease companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Moderate and Severe Chronic Kidney Disease Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Mid Stage Products (Phase II)
Comparative Analysis
KBP-5074: KBP Bioscience
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Moderate and Severe Chronic Kidney Disease Key Companies
Moderate and Severe Chronic Kidney Disease Key Products
Moderate and Severe Chronic Kidney Disease- Unmet Needs
Moderate and Severe Chronic Kidney Disease- Market Drivers and Barriers
Moderate and Severe Chronic Kidney Disease- Future Perspectives and Conclusion
Moderate and Severe Chronic Kidney Disease Analyst Views
Moderate and Severe Chronic Kidney Disease Key Companies
Appendix
Executive Summary
Moderate and Severe Chronic Kidney Disease: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Moderate and Severe Chronic Kidney Disease – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Moderate and Severe Chronic Kidney Disease companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Moderate and Severe Chronic Kidney Disease Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Mid Stage Products (Phase II)
Comparative Analysis
KBP-5074: KBP Bioscience
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Moderate and Severe Chronic Kidney Disease Key Companies
Moderate and Severe Chronic Kidney Disease Key Products
Moderate and Severe Chronic Kidney Disease- Unmet Needs
Moderate and Severe Chronic Kidney Disease- Market Drivers and Barriers
Moderate and Severe Chronic Kidney Disease- Future Perspectives and Conclusion
Moderate and Severe Chronic Kidney Disease Analyst Views
Moderate and Severe Chronic Kidney Disease Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Moderate and Severe Chronic Kidney Disease
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Moderate and Severe Chronic Kidney Disease
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Moderate and Severe Chronic Kidney Disease
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Moderate and Severe Chronic Kidney Disease
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
